Search Results

Featured Stories

Toggle

Showing 25 of 128 results

“This ‘invisible pandemic’ is one of the biggest global health challenges”

Dr Riad Dirani specializes in researching the clinical, economic and human impact of non-communicable diseases (NCDs), such as heart disease, stroke, cancer, asthma and diabetes. Riad outlines how his work is helping tackle an “invisible epidemic” and how his Dad’s unexpected experience with diabetes led him to a career in the pharma industry.

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)

Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the...

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner t

SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals today launched a new program to...

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Associa

Findings evaluate efficacy and safety of AUSTEDO in postmenopausal women with tardive dyskinesia (TD) for up to 3 years Two studies evaluate the psychological, social and physical impact of TD on...

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Ann

Three posters evaluate the long-term safety and efficacy of AUSTEDO ® (deutetrabenazine) tablets as well as the physical, psychological, and social impact of tardive dyskinesia on patients One stud...

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targ

Environmental, Social and Governance (ESG) efforts integrated into business strategy with strengthened oversight, robust targets and sustainability-linked bond (SLB) Progress toward targets to...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

16 presentations will examine safety and efficacy of AJOVY and AUSTEDO TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industrie...

Research Finds COVID Pandemic Worsened Health Equity Gap

National survey conducted by the Morehouse School of Medicine and Teva Pharmaceuticals shows intensified impacts among vulnerable populations driven by lack of access to care   About 50% of...

Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and

$5 billion bond is the largest of its kind from any sector and the first issued by a generic medicines company The bond is tied to targets that include improving access to medicines in low- and...

Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

New Phase 3 RISE study data, post hoc analyses and open-label extension studies to be presented underscore company’s heritage in and commitment to mental health and neuroscience TEL AVIV, Israel &...

Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disp

Extension analyses observed patients taking AJOVY experienced a reduction in migraine and headache days and evaluated disability and health-related quality of life Online symposium to highlight...

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors Ma

AMSTERDAM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic...

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva...

Teva Sets Ambitious Long-Term Environmental Goals As Part of Renewed ESG Strategy

January 12, 2021 /3BL Media/  - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced long-term environmental sustainability commitments and targets to provide direction and drive...

Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fre

Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks Pooled Phase 3 results examined change...

Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injectio

AJOVY data highlight efficacy and safety in difficult-to-treat migraine GALA open-label extension study evaluates 7-year efficacy and safety results of COPAXONE Teva Pharmaceutical Industries Ltd....

China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia i

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has approved AUSTEDO® (Deutetrabenazine Tablets) for the...